Anzeige
Mehr »
Mittwoch, 13.05.2026 - Börsentäglich über 12.000 News
Bahnbrechende KI-Lösung "Ohne Nadelstiche" als Ersatz für herkömmliche Bluttests "unlocked"?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40LQ4 | ISIN: US01626L2043 | Ticker-Symbol: 5WK0
Tradegate
13.05.26 | 08:13
5,410 Euro
-2,17 % -0,120
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ALIGOS THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ALIGOS THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
5,6205,77021:06
5,6205,81020:40

Aktuelle News zur ALIGOS THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08:12Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 20263
FrAligos Therapeutics GAAP EPS of -$2.21 beats by $0.04, revenue of $2.83M beats by $2.5M1
DoAligos Therapeutics, Inc. - 10-Q, Quarterly Report-
DoAligos Therapeutics, Inc. - 8-K, Current Report-
24.04.Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)7
21.04.Aligos Therapeutics, Inc. - 8-K, Current Report1
17.04.H.C. Wainwright reiterates Aligos stock rating on China deal15
ALIGOS THERAPEUTICS Aktie jetzt für 0€ handeln
17.04.Aligos and Xiamen Amoytop sign deal for HBV therapy4
16.04.Jefferies reiterates Aligos Therapeutics stock rating on China deal10
16.04.Aligos Therapeutics Says China Pact Puts HBV Drug In Focus Amid Trial Updates2
16.04.Aligos sells China rights to HPV drug to hepatology player Amoytop in $445M deal2
16.04.Aligos Therapeutics jumps 22% on Greater China deal for Hepatitis B drug2
16.04.Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection178Aligos to receive an upfront payment of $25M USDUp to $420M USD in clinical, regulatory, and sales milestones along with tiered, high single-digit royaltiesAmoytop to fund its development program...
► Artikel lesen
14.04.Aligos receives FDA fast track designation for hepatitis B drug18
14.04.Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation179Received FDA Fast Track Designation for pevifoscorvir sodium for the treatment of chronic hepatitis B virus infectionHBeAg- cohort sample size increased to optimize powering; futility criteria not...
► Artikel lesen
14.04.Aligos Therapeutics, Inc. - 8-K, Current Report-
19.03.Jefferies startet Aligos-Aktie mit "Kaufen" und sieht Potenzial in Hepatitis-B-Medikament26
19.03.Jefferies initiates Aligos Therapeutics stock rating at Buy on hepatitis B drug potential2
05.03.Aligos Therapeutics GAAP EPS of -$1.91 beats by $0.124
05.03.Aligos Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
Weiter >>
48 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1